STAb Therapeutics, a biotechnology company that develops novel immune redirecting cell therapies for cancer, announces that Dr. Carolina Pola has been appointed as CEO of the Company.
Dr. Pola brings a biobusiness perspective and expertise to STAb Therapeutics to develop and deploy the strategic plan for the growth of the Company. She has developed an extensive investor and biotech network within Spain and abroad. Dr. Pola has more than 10 years of experience in the biotech ecosystem creating strategic approaches for the development and commercial exploitation of early-stage technologies and funding of innovative approaches in biomedicine.
She has more than 10 years of experience in the US where she trained at New York University during her graduate studies and was Scientific Editor at Nature Medicine leading the front-half section. During this time, Dr. Carolina Pola nurtured and broaden her scientific acumen in biomedicine, especially in oncology. Upon her return to Spain in 2014, she was Director of Corporate and Scientific Communications at PharmaMar, Director of Innovation at the Spanish National Cancer Research Center (CNIO), Innovation Strategist at Kaudal and Head of Intellectual Property at Arquimea. She is currently collaborator of the Scientific Committee of the Ramón Areces Foundation, Associate of the business angel association WA4STEAM and Adjunct Faculty at IE University.
“Carolina’s arrival comes at the right moment to propel STAb’s development and growth. Our scientific results achieved so far at the preclinical level will be turned into business milestones with her experience and track record in developing strategic vision and securing the support of new partners and investors,” says Dr. Belen Blanco, Co-Founder and CSO of STAb Therapeutics.
“This is a unique opportunity to join a remarkable team of scientific founders. Our innovative technological approach to redirecting the immune system in oncology is very close to be tested in the clinical setting, a milestone for STAb that we will witness soon. I am thrilled to get onboard at this exciting time. My goal is to ensure that STAb quickly and efficiently develops all its technological potential to target unmet clinical needs, maximize patients’ lives and penetrate the cell therapy market as a major innovator player,” says Dr. Carolina Pola, now CEO of STAb Therapeutics.
STAb Therapeutics is a new spin-off of the University Hospital 12 de Octubre (H12O) that was launched with the support of CRIS Foundation to bring a novel cell therapy technology to the market and benefit patients with hematological and solid tumors. The technology will be developed as a platform given its versatility and technological foundation.